Timing note: IDEX has scheduled its Q2 results for Wednesday, July 29, 2026, before the market opens, followed by its earnings call at 9:00 a.m. ET. Because July 29 is the current date—not tomorrow—this preview is framed as immediately ahead of the release. (investors.idexcorp.com)
IDEX enters Q2 with unusually strong momentum in Health & Science Technologies, particularly across data centers, semiconductors, and space and defense. The central question is no longer whether these businesses are growing; it is whether that strength can remain durable enough to offset still-muted short-cycle industrial demand and improve the company’s overall growth profile.
A result merely matching Q2 guidance would be respectable. For the stock to react positively, however, investors will probably want at least one of the following:
The risk is that the strong Q1 order intake represented some pull-forward, while mix from lower-margin acquired growth businesses limits earnings conversion. With the shares trading at roughly 26.5 times the $8.48 FY2026 consensus EPS estimate, expectations are already reasonably demanding. (barchart.com)
| Metric | Q2 2026 reference point |
|---|---|
| Management organic-sales guidance | +3% to +4% |
| Management adjusted EBITDA-margin guidance | 26.5% to 27.0% |
| Management adjusted EPS guidance | $2.07 to $2.12 |
| Street adjusted EPS estimate | Approximately $2.10–$2.11 |
| Street revenue estimate | Approximately $905 million |
| Q2 2025 revenue | $865.4 million |
| Q2 2025 adjusted EPS | $2.07 |
| Q2 2025 adjusted EBITDA margin | 27.4% |
| FY2026 organic-sales guidance | +3% to +4% |
| FY2026 adjusted EPS guidance | $8.35 to $8.55 |
| FY2026 consensus EPS | Approximately $8.48 |
Consensus sources place Q2 EPS near the high end of management’s range and revenue around $905 million. (benzinga.com)
Reported revenue around $905 million would imply roughly 5% year-over-year growth. That is consistent with management’s 3%–4% organic outlook plus acquisition and currency contributions.
IDEX set a high bar in the first quarter:
The Q1 book-to-bill ratio was approximately 1.11, with order strength concentrated in HST. That backlog build gave management more confidence in the full-year outlook, but it also means investors will be sensitive to any Q2 order deceleration.
Health & Science Technologies accounted for approximately 45% of Q1 revenue and produced the company’s strongest growth:
Growth was broad across several advantaged markets:
Management indicated that HST’s order book provides visibility not only through the remainder of 2026 but into 2027. Customers in these markets are providing longer-range forecasts because they need IDEX to prepare capacity, labor, and materials for ramping programs.
A strong report would likely include:
IDEX’s recent acquisitions—particularly Mott, Muon, and Micro-LAM—are contributing to growth but remain below the HST segment’s longer-term margin potential. Management expects 8020 portfolio work, business pruning, and operating leverage to improve their profitability.
HST’s incremental EBITDA margin has recently been in the low-to-mid-30% range. Management has suggested it could move closer to 40% over time, but not necessarily during 2026. Investors should therefore distinguish between:
Fluid & Metering Technologies was mixed in Q1:
The strongest areas were municipal water, high-purity water used in semiconductor applications, mining, and pumps. Chemical markets and parts of general industrial demand remained soft.
Management characterized short-cycle trends as improving through Q1: January was weak, February improved, March was stronger, and April held around the March level. However, not all of IDEX’s industrial “diagnostic” businesses were improving together, preventing management from declaring a broad cyclical inflection.
Management’s full-year outlook assumes roughly flat FMT organic growth. Consequently, even modest positive growth in the second half could provide upside to current guidance. Conversely, a weak order result would reinforce the view that Q1 strength was timing-related rather than the start of a broader recovery.
Fire & Safety/Diversified Products posted:
North American fire-and-rescue demand remained strong, and Europe had returned to a more normal level. Those positives were offset by lower dispensing-project volumes and difficult comparisons.
The full-year FSDP outlook is approximately flat. The likely success criteria are therefore modest:
A material FSDP recovery is not embedded in guidance, but additional weakness—particularly in dispensing—could offset upside elsewhere.
Q2 adjusted EBITDA-margin guidance of 26.5%–27.0% compares with 27.4% in Q2 2025, implying a year-over-year decline of 40–90 basis points even with higher revenue.
That apparent disconnect reflects several factors:
An adjusted EBITDA margin above 27% would be a meaningful positive because it would suggest that productivity, price/cost, and operating leverage are overcoming mix pressure faster than expected.
Conversely, revenue upside accompanied by margins below guidance would be lower-quality growth and may not support a positive stock reaction.
IDEX often enters a quarter only about 50% booked, especially in the faster-turn FMT and FSDP businesses. This makes current orders an important indicator of near-term direction.
Investors should focus on:
A modest EPS beat with weakening orders could be poorly received. An in-line quarter with another strong backlog build could be more valuable for the longer-term earnings outlook.
Management’s current FY2026 outlook is:
The $8.48 consensus EPS estimate sits close to the midpoint of guidance. That suggests the market does not require a major raise but does expect IDEX to deliver near the middle-to-upper half of the range.
Given that Q1 already prompted a material guidance increase, a simple reiteration would not necessarily be disappointing. The quality of the segment commentary will determine whether investors view the unchanged outlook as conservative or as evidence that Q1 represented the peak growth quarter.
Q1 free cash flow was $86 million, down slightly year over year despite higher earnings. The primary issue was working capital:
Q2 is normally a stronger cash-generating period. Investors should look for:
IDEX ended Q1 with approximately $1.1 billion of liquidity and gross leverage around 2 times. The company therefore retains capacity for bolt-on acquisitions while maintaining dividends and repurchases. Still, investors should watch whether repurchases are being funded partly through additional revolver borrowings rather than internally generated cash.
The setup is fundamentally favorable but not low-expectation.
IDEX’s strategic pivot toward higher-growth applications is showing tangible results, with HST benefiting from AI infrastructure, semiconductor capital spending, optical technologies, and space and defense. The Q1 order performance supports another solid Q2 and makes a significant miss less likely absent program timing or mix issues.
However, three things could limit upside:
The best outcome is not simply EPS above $2.12. It is a combination of sustained HST orders, improving HST margin conversion, and evidence that FMT’s short-cycle businesses are beginning to participate. That would make the company’s 3%–4% full-year organic-growth target look conservative and increase confidence that IDEX can carry stronger growth into 2027.